Delivery Order SPE2DB22D1017-SPE2DB25FG9BD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count units) valued at $1,240.25. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The order is scheduled for completion by July 29, 2025, with performance to be executed from AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents...
- The Defense Logistics Agency awarded a $1,459.36 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count packages). This firm fixed-price delivery order, with a completion date of September 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026. The contract was...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count) with a ceiling value of $4,953.94. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) with a ceiling value of $1,541.01. This is a firm fixed-price delivery order with no set-aside designation, completed competitively under open procurement requirements. The contract calls for delivery to Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120 count) with a ceiling value of $2,765.95. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 19, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets in a quantity of 90 tablets. This firm fixed-price delivery order, valued at $1,642.98, is scheduled for completion by September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was awarded without a set-aside designation, indicating it was competitively awarded among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count units) with a contract ceiling value of $3,174.90 and a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) on September 9, 2025, with a ceiling value of $18,135.41. This firm fixed price delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120 count) with a ceiling value of $2,189.18. This is a firm fixed-price delivery order placed under a non-competitive set-aside designation, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. The delivery order is scheduled for ultimate completion on August 28,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count packages) valued at $2,733.13. This non-competitive, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services under the company's existing...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9BDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count) with a ceiling value of $2,608.99. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is set for ultimate completion by August 7, 2025, and will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 value through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency, U.S. Coast Guard, and other government entities. The company maintains an extensive portfolio of pharmaceutical products and medical supplies under its DLA prime vendor contract, including brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains. This specific delivery order for Alfuzosin HCL ER tablets represents one of numerous competitively awarded transactions the company fulfills through its comprehensive global pharmaceutical support vehicle supporting military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/6/25 |